Eva Goncalvesová
Pharmacological treatment of heart failure has changed only very slightly during the last ten years. From the large number
of drugs that were studied for the treatment of chronic heart failure ivabradin only reach the filed of clinical use.
Currently, there are several tents of new molecules in the various stages of development. Most are expected from research
of new drugs for the treatment of acute heart failure and heart failure with preserved left ventricular ejection
fraction. For these patients or clinical situations we still do not have drugs that have scientifically shown to be effective,
particularly in terms of positive impact on patients survival. In the near future approval for clinical usage of LCZ696
is pending. LCZ 696 is a combination angiotensin receptor blocker valsartan and neprilysin inhibitor. The extensive clinical
trial (PARADIGM-HF) showed that LCZ696 in patients with chronic heart failure based on left ventricular systolic
dysfunction significantly reduces the number of deaths from cardiovascular causes or hospitalization for heart failure.
A study was stopped prematurely at a median follow-up of 2.7 years because of clear benefit from the use of LCZ696.